Asphaug L, Akslen LA, Blix ES, Boge B, Borgen EF, Brekke MB, Falk RS, Geitvik GA, Gilje B, Gravdehaug B, Heie A, Janssen E, Kiserud CE, Kursetgjerde T, Langerød A, Lømo J, Mannsåker B, Mortensen E, Olsson P, Porojnicu AC, Raj SX, Roe OD, Russnes HEG, Skjerven HK, Songe-Møller Set al.(2025) Cost-effectiveness of Prosigna for Adjuvant Treatment Decisions in Early Breast Cancer: Healthcare Sector and Societal Perspectives Clin Breast Cancer, 25(6), e721-e730 DOI 10.1016/j.clbc.2025.04.011, PubMed 40348620
Fjørtoft MO, Garred Ø, Lingjærde OC, Lande KT, Ottestad L, Bergheim IR, OSBREAC, Lømo J, LaMont C, Myklebust JH, Russnes H, Huse K, Rye IH(2025) Single-cell analysis reveals tumour size as a key driver of immune cell profile alterations in primary breast tumours and corresponding lymph nodes BJC Rep, 3(1), 35 DOI 10.1038/s44276-025-00152-3, PubMed 40394379
Haj Mohammad SF, van der Pol H, Vrdoljak E, Lassen U, Ojamaa K, Jalkanen K, Verlingue L, Stenzinger A, Patócs A, Curigliano G, Baltruškevičienė E, Helland Å, Russnes HG, Ługowska I, Mainoli B, Edsjö A, Lonardi E, Taskén K, Gelderblom H(2025) A comprehensive assessment of the existing landscape of personalized cancer medicine in the European Union, on behalf of the PCM4EU consortium ESMO Open, 10(11), 105872(in press) DOI 10.1016/j.esmoop.2025.105872, PubMed 41197434
